Similar articles

• Type 2 myocardial infarction in clinical practice.

  Baron T, Hambraeus K, Sundström J, Erlinge D, Jernberg T, Lindahl B; TOTAL-AMI study group. Baron T, et al. Heart. 2015 Jan;101(2):101-6. doi: 10.1136/heartjnl-2014-306093. Epub 2014 Oct 20. Heart. 2015. PMID: 25331532
• Coronary Revascularization in the Current Era.

  Weiss S, Weintraub W. Weiss S, et al. Prog Cardiovasc Dis. 2015 Nov-Dec;58(3):227-9. doi: 10.1016/j.pcad.2015.10.001. Epub 2015 Oct 22. Prog Cardiovasc Dis. 2015. PMID: 26471932 No abstract available.
• Antiplatelet agents in ischemic heart disease.

  May CH, Lincoff AM. May CH, et al. Handb Exp Pharmacol. 2012;(210):495-518. doi: 10.1007/978-3-642-29423-5_20. Handb Exp Pharmacol. 2012. PMID: 22918744 Review. No abstract available.
• Treatment of diabetic patients with non-ST-elevation myocardial infarction.

  Barbato E. Barbato E. J Cardiovasc Med (Hagerstown). 2011 Apr;12(4):268-9. doi: 10.2459/JCM.0b013e328344e659. J Cardiovasc Med (Hagerstown). 2011. PMID: 21372738
• [Glycoprotein IIb/IIIa blockers. Their usefulness in current cardiovascular therapeutics].

  López Cuéllar J. López Cuéllar J. Arch Inst Cardiol Mex. 1999 May-Jun;69(3):272-81. Arch Inst Cardiol Mex. 1999. PMID: 10529862 Review. Spanish. No abstract available.